About AnnJi Pharmaceutical Co. Ltd
Dedicated to New Drug Development in Dermatology & Neurology
Our Advisor
Hardy W. Chan Ph.D.
A veteran of the US pharmaceutical industry, Dr. Hardy W. Chan was the Vice President of Research and Director of Biotechnology at Syntex, a company headquartered in Palo Alto, California, USA which was subsequently acquired by Roche in 1994.
Dr. Chan co-founded ScinoPharm Taiwan and served as its CSO for 13 years; he later joined Tanvex Pharmaceuticals and served as its CEO for 3 years. Since 2014, Dr. Chan has established Allianz Pharmascience, Ltd., Nano Targeting & Therapy (NTT) Biopharma Inc. and Helios Bioelectronics Inc.
With decades of experience at the forefront of the pharmaceutical industry, Dr. Chan enjoys translating novel scientific discoveries into compelling investment opportunities. Dr. Chan received a Ph.D. in Biochemistry from the University of Wisconsin-Madison, USA.
Masahisa Katsuno Professor/MD
Professor Katsuno serves in the Department of Neurology at Nagoya University Graduate School of Medicine, Japan. He is an internationally renowned physician-scientist in the clinical research field of polyglutamine diseases and has over 400 peer-reviewed publications in high impact journals. He developed one of the original spinal bulbar and muscular atrophy (SBMA) mouse models and was one of the leading principal investigators in SBMA clinical studies of Leuplin SR® (leuprorelin acetate) that obtained new drug approval in Japan.
Professor Katsuno received commendation for science and technology from the Ministry of Education, Culture, Sport, Science and Technology in Japan.
Nan-Horng (Stan) Lin Ph.D.
Dr. Stan Lin has over 30 years of leadership experiences in pharmaceutical and biotechnology industries. Dr. Lin has extensive experiences in bringing drug discovery through various stages of drug development. Recently Dr. Lin’s has held leadership positions as the executive vice president of CHO Pharmaceutical, a biotech company developing Biologics product, the senior vice president of Crown Biosciences, a reputable CRO, and the CSO of Medicilon, a diverse drug discovery CRO and the executive director of the Development Center for Biotechnology in Taiwan.
Dr. Lin is an experienced research scientist and leader has worked in various US big pharmaceutical companies, including Abbott Laboratories and Bayer USA. He developed numerous clinical candidates that advanced to late clinical phases and obtained more than 80 patents as well as published more than 70 peer reviewed papers.
Dr. Lin currently is AnnJi’s advisor in chemistry, manufacturing and controls and drug development.
Shiao-ping Lu
MS
Ms. Shiao-ping Lu has over 30 years of clinical development experiences in pharmaceutical and biotechnology industries; served as the head of Biostatistics at Alector, Portola Pharmaceutical and held senior role at Gilead Science, and CV Therapeutics.
Ms. Lu is an experienced clinical scientist, with expanded leadership roles and responsibilities in drug development, including setting clinical development strategy, designing and executing early and late-stage clinical trials, defending company position throughout regulatory reviews by the FDA and EMEA, and collaborating with medical affairs and commercial colleagues for product launch.
She was a key contributor to many successful INDs, breakthrough designations and fast track reviews, as well as multiple approvals of NDA/BLA/MAA, including Andexxa®, Bevyxxa®, Ranexa®, Vistide® and Qutenza®. She was instrumental in many technical due diligences on the business development front and participated in two successful IPO’s.
Mr. Ryuichi Shoji
Mr. Ryuichi Shoji received a degree in MBA in International Business and BS in Biochemistry, and has over 40 years of experience in international pharmaceutical business working for Taisho Pharmaceutical and Fuji Yakuhin. He established branch offices for Taisho in Europe and US, where he successfully executed multiple clinical studies. Mr. Shoji has a successful track record of more than 20 product in- and out-licensing deals made among multinational pharmaceutical companies and venture companies, including pharma companies, such as Novartis and Eisai.
Elvis Yang, PhD
Dr. Yang has more than 12 years of experience in the biomedical industry. He has led and participated in the development of novel in vitro diagnostic medical devices from research stage to commercialization, as well as established global marketing channels for direct sales and distributors.
Dr. Yang held a BS degree in Animal Science and received a Ph.D. in Biochemistry and Molecular Biology from National Taiwan University.
